What is the elephant in the room when considering new therapies for fungal diseases?

Autor(es)

Chaves, Alison Felipe Alencar ^[1] ; Xander, Patricia ^[2] ; Romera, Lavinia Maria Dal'Mas ^[3] ; Fonseca, Fernando Luiz Affonso ^[2] ; Batista, Wagner Luiz ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo - Brazil

^[2] Univ Fed Sao Paulo, Dept Pharmaceut Sci, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept Microbiol, Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CRITICAL REVIEWS IN MICROBIOLOGY; v. 47, n. 3 JAN 2021.
• Citações Web of Science: 0

Resumo

The global scenario of antimicrobial resistance is alarming, and the development of new drugs has not appeared to make substantial progress. The constraints on drug discovery are due to difficulties in finding new targets for therapy, the high cost of development, and the mismatch between the time of drug introduction in a clinic and microorganism adaptation to a drug. Policies to address neglected diseases miss the broad spectrum of mycosis. Society is not aware of the actual threat represented by fungi to human health, food security, and biodiversity. The evidence discussed here is critical for warning governments to establish effective surveillance policies for fungi. (AU)

• Processo FAPESP: 15/09727-6 - Desenvolvimento e caracterização de mutante ”PbKU70 para o fungo patogênico humano Paracoccidioides brasiliensis
• Beneficiário: Alison Felipe Alencar Chaves
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/04592-0 - Avaliação das proteínas S-nitrosiladas do fungo Paracoccidioides brasiliensis após estresse nitrosativo e identificação de potenciais vias de sinalização redox
• Beneficiário: Wagner Luiz Batista
• Modalidade de apoio: Auxílio à Pesquisa - Regular